Prior authorization required for medical-benefit IG requests

Prior authorization is required whenever a requested immunoglobulin product is reviewed under the member's medical benefit; the request will be evaluated against this policy's clinical criteria to determine medical necessity.

Include indication-specific clinical documentation with PA

Submit a prior authorization request that includes clinical documentation demonstrating the specific indication and that the member meets the policy's listed clinical and laboratory criteria (e.g., diagnosis, IgG thresholds, prior therapy trials, timing of symptoms where required).

PA approvals have indication-specific durations

Prior authorization approvals are issued for indication-specific durations — initial and continuation approval periods vary by diagnosis (examples: initial CIDP/CIDP-like trials up to 12 weeks with 1-year continuation; GBS limited to one 5‑day course).

Step therapy and PA required for non-preferred IG agents

Prior authorization is required and subject to step-therapy rules: requests for non-preferred IVIG or SCIG agents must document trials of preferred agents or meet specified clinical rationales for override (for example, intolerance, severe IgA deficiency, or other listed reasons).

• Non-preferred IVIG: documentation of trial and inadequate response or intolerance to two preferred IVIG agents, or acceptable clinical rationale (e.g., severe IgA deficiency <7 mg/dL).
• Non-preferred SCIG-only: documentation of trials of two preferred SCIG agents or justification per policy (e.g., difficult venous access with rationale).

HCPCS codes for IG products are listed in the policy

The policy lists HCPCS codes for immune globulin products; use the listed HCPCS/J-codes or designated unclassified codes exactly as shown when requesting and billing IG products.

Submit claims/PA using the listed J‑codes

Claims and prior authorization requests should use the product-specific HCPCS J-codes shown in the policy (for example J1558, J1559, J1561, J1566, J1568, J1569, J1572, J1575) that correspond to the exact product and billing unit.

HCPCS code descriptors for PA and billing reference

This policy section provides HCPCS descriptors that are relevant for PA and billing (for example J1559, J1561, J1566, J1568, J1569, J1572, J1575, J1576) and should be referenced when completing authorization/billing workflows.

Use listed HCPCS codes that identify IG products

Use the HCPCS codes listed (examples: J1561, J1566, J1568, J1569, J1572, J1575, J1576, J1599) on claims and when identifying the administered immune globulin product for benefit adjudication.

Use exact HCPCS codes (including J3590 when specified) on claims

Submit claims using the exact HCPCS codes corresponding to the administered product (examples listed: J1566, J1568, J1569, J1572, J1575, J1576, J1599; J3590 when specified as Qivigy) to ensure correct claim processing and benefit assignment.

Code-based PA and claims: include product and home‑infusion codes

Prior authorization requests and claims should use the specific HCPCS codes listed (for example J1566, J1568, J1569, J1572, J1575, J1576, J1599) and include Q2052 when home infusion supplies/services are applicable.

Use these HCPCS/J‑codes for claims and PA

Use the listed HCPCS/J-codes exactly as specified for immune globulin products and for associated home administration supplies when submitting prior authorization requests and claims.

• Include Q2052 for home infusion supplies when applicable.

Reference exact HCPCS/J/Q/S codes in PA (including S9338 for home infusion)

Reference the exact HCPCS/J/Q/S code requested (for IVIG/SCIG or home infusion) in prior authorization submissions; S9338 is used for home infusion per diem services where applicable.

• Include S9338 for home infusion service per diem when applicable.
• Specify the exact J- or Q-code for the IG product being requested.

PA and coding must match listed J/Q/S codes

Prior authorization and accurate coding must use the listed J-codes, Q2052 and S9338 (as applicable) to ensure correct benefit adjudication and assignment of services to the medical benefit.

PA decisions reflect step‑therapy and coding updates

Prior authorization decisions incorporate step therapy and coding updates; providers should account for recent code additions/changes in the policy when requesting non‑preferred agents or home infusion services.

PA may depend on product preference (preferred vs non‑preferred)

Anthem classifies immunoglobulin products as preferred or non‑preferred by benefit and effective date; prior authorization requirements (including step‑therapy trials and overrides) may vary depending on the product's preference status.

• Check the Commercial or Medicare preferred/non‑preferred lists for the applicable effective date before requesting a non‑preferred agent.

Step‑therapy expectations: reserve IG after alternative therapy trials

For many autoimmune and inflammatory indications, IG is reserved for patients who have had inadequate response, intolerance, or contraindication to standard alternatives; document prior therapies and failures in the PA submission.

Preferred‑product requirement may apply despite meeting clinical criteria

Plans may require use of a preferred immunoglobulin agent(s) even when clinical criteria are met; obtain authorization for non‑preferred products only after meeting step‑therapy/override requirements.

Required documentation to support non‑preferred IG requests

When approval is sought for a non‑preferred IVIG or SCIG agent, include documentation showing trials and inadequate response/intolerance to two preferred agents or allowed clinical reasons (for example severe IgA deficiency <7 mg/dL, hypersensitivity, hemolysis or renal dysfunction) to support an override.

• List dates and outcomes of preferred-agent trials and provide objective evidence of intolerance or inadequate response.

Include electrodiagnostic and objective measures for neurologic indications

Electrodiagnostic test results (e.g., NCS, RNS, SFEMG) and other objective measures used to confirm neurologic diagnoses such as CIDP should be supplied with authorization requests when applicable.

• For CIDP, include electrodiagnostic findings consistent with EFNS/PNS or AAN parameters and documentation of symptom duration (>2 months).

Required clinical and laboratory documentation for PA

Providers must document diagnosis, relevant laboratory results (for example pre‑treatment total serum IgG, IgG subclass levels, CD3+ T cell count when indicated), history of infections or vaccine response, and prior therapy trials as applicable in the PA submission.

• Include total serum IgG and relevant subclass values when indicated.
• For transplant/HCT and some oncology indications, include IgG thresholds (e.g., IgG <400–500 mg/dL where specified).

Document objective clinical response for continuation PA

Continuation requests must demonstrate objective clinical improvement or ongoing functional impairment as specified per condition (for example: clinically significant exam improvement for CIDP, MMN, MG; stability on current dose or worsening with dose decrease).

Non‑preferred IG requests: detail preferred‑agent trials or clinical rationale

Documentation for non‑preferred IG requests must show trials and inadequate response or intolerance to the specified preferred agents (commonly two), or provide a clinical rationale for why preferred agents are unacceptable.

• Examples of acceptable rationale: severe IgA deficiency (<7 mg/dL), IgA antibodies, hypersensitivity to excipients, clinically significant hemolysis or renal dysfunction with preferred agents.

Specify exact HCPCS J‑code and unit size on PA and claims

Use the exact HCPCS J-code that corresponds to the immune globulin product and billing unit when submitting PA requests and claims (examples provided in the policy: J1558 for Xembify 100 mg, J1559 for Hizentra 100 mg, and multiple 500 mg IV codes).

Include product HCPCS and home‑infusion supply/service codes (Q2052, S9338)

Include HCPCS code(s) for the IG product and Q2052 for home infusion supplies when applicable; when home infusion services are provided, reference S9338 for home infusion per‑diem services.

• Examples: J1568, J1569, J1572, J1575, J1576, J1599 and Q2052 for supplies; S9338 for home infusion per diem.

Denial risk: failure to meet clinical or laboratory criteria

PA approvals may be denied if requests do not meet the policy's clinical criteria, laboratory thresholds (e.g., required IgG values), documented prior‑therapy requirements, or lack required objective documentation.

• Examples of denial triggers: missing diagnostic criteria, absent required IgG thresholds, no documented trials of required alternative therapies, or absence of objective response data for continuation requests.

Denial risk: non‑approved indications

Requests for non‑approved indications listed in the policy (for example Alzheimer’s disease, immune optic neuropathy except MOG‑related NMOSD, multiple sclerosis, PANDAS) are not approvable per the policy.

Denial risk for non‑preferred IVIG without required trials

Requests for non‑preferred IVIG agents risk denial unless documentation shows trials and inadequate response or intolerance to two preferred IVIG agents or other allowed clinical reasons as specified in policy.

Denial risk for non‑preferred SCIG without required trials or justification

Requests for non‑preferred SCIG‑only agents risk denial if documentation does not demonstrate trials of two preferred SCIG agents or acceptable clinical justification (examples: severe IgA deficiency, hypersensitivity, difficult venous access with rationale).

Coding mismatch or use of unclassified codes may trigger denial

Using an unlisted or incorrect HCPCS/J‑code (for example using J3590 or a NOC code when a product‑specific J‑code exists) may delay processing or trigger claim denial; ensure the product‑specific code is used when available.

• Qivigy may be reported as J1599 or, when specified, J3590/C9399 per the policy — confirm the correct code mapping in the policy when requesting/billing.

Coding errors or outdated mappings risk claim denial

Missing or incorrect HCPCS/J‑code specification (for example using an unlisted code when a product‑specific J‑code exists) may trigger processing denials; verify codes against the current policy list and recent coding updates.

Verify current step‑therapy and code updates before PA submission

Step‑therapy table updates and coding changes have occurred periodically; providers should confirm the current preferred/non‑preferred product lists and code mappings for the member's benefit and the policy effective dates before submitting PA requests.

• Document history shows multiple recent updates (e.g., additions of J1572, J1599 and removal/changes for Yimmugo/Gammagard ERC).